HIV-1 neutralizing antibody b12 paratope (b12 paratope)

The b12 antibody paratope is the specific antigen-binding region of the human monoclonal antibody IgG1 b12, which was one of the first identified broadly neutralizing antibodies (bnAbs) against HIV-1 (Burton et al., 1994). This paratope is directed toward the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein gp120, a highly conserved region essential for viral entry into host cells (Saphire et al., 2001). Structurally, the b12 paratope is distinguished by a unique, long heavy-chain complementarity-determining region 3 (CDR H3) that reaches through the dense glycan shield of the HIV-1 envelope to reach the recessed CD4bs (Zhou et al., 2007). By binding to this site, the paratope sterically blocks the interaction between gp120 and the host's CD4 receptor, thereby preventing the virus from infecting T-lymphocytes. Although the paratope itself is not a therapeutic target in the traditional sense, its structural configuration serves as a critical template for reverse vaccinology efforts aimed at designing immunogens that can elicit similar protective antibodies. The study of the b12 paratope has provided fundamental insights into the mechanisms of HIV-1 neutralization and the structural vulnerabilities of the viral envelope.

Other names

IgG1 b12 paratopeb12 idiotypeb12 CDR regionHIV-1 b12 antibody binding site

The b12 paratope neutralizes HIV-1 by binding to the CD4-binding site (CD4bs) on the gp120 surface protein. This binding mimics the host CD4 receptor interaction, effectively blocking the virus from attaching to and entering CD4+ T-cells (Burton et al., 1994; Saphire et al., 2001).